Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease-Reference-Cited by-同舟云学术

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Published:2016-11-25 Issue:11 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

MacDonald John K¹²,Nguyen Tran M¹,Khanna Reena²,Timmer Antje³

Affiliation:

1. Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6

2. University of Western Ontario; Department of Medicine; London ON Canada

3. Carl von Ossietzky University of Oldenburg; Department of Health Services Research; Oldenburg Germany 26111

Publisher

Wiley

Subject

Pharmacology (medical)

Reference78 articles.

1. Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies;Adedokun;Gastroenterology,2016

2. Ustekinumab as induction and maintenance therapy for Crohn's disease;Feagan;New England Journal of Medicine,2016

3. Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: Results from uniti-1 induction, uniti-2 induction, and imuniti maintenance studies;Li;Gastroenterology,2016

4. A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti-TFNalpha: UNITI-1;Sandborn;Inflammatory Bowel Diseases,2016

5. Assessment of serum C-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohns disease: Results from the IM UNITI maintenance study;Sandborn;Gastroenterology,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recomendaciones basadas en el manejo de pacientes con diagnóstico de enfermedad de Crohn en el contexto peruano. Documento de posición de la Asociación Peruana para el Estudio del Intestino (ASPEIN);Revista de Gastroenterología del Perú;2024-06-26

2. A Crohn-betegég terápiás stratégiája;Orvosi Hetilap;2024-03-12

3. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

4. Comparative diet-gut microbiome analysis in Crohn’s disease and Hidradenitis suppurativa;Frontiers in Microbiology;2023-11-10

5. Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease;Frontiers in Medicine;2023-04-11